We are live on ! Find out more
FTXH icon

First Trust Nasdaq Pharmaceuticals ETF

22 hedge funds and large institutions have $7.55M invested in First Trust Nasdaq Pharmaceuticals ETF in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.76% more ownership

Funds ownership: 39.73%43.5% (+3.8%)

7% less capital invested

Capital invested by funds: $8.12M → $7.55M (-$573K)

8% less funds holding

Funds holding: 2422 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
7
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SWP
26
Stratos Wealth Partners
Ohio
-$228K -8,361 Closed
IAIM
27
International Assets Investment Management
Florida
-$72.5K -2,662 Closed
UBS Group
28
UBS Group
Switzerland
-$790 -29 Closed

FTXH Hedge Fund Activity: Q3 2024 in Review

22 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2024, worth a combined $7.55M — down 7.1% from $8.12M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of FTXH and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was NewEdge Advisors, opening a new position worth an estimated $611K. The largest seller was Royal Bank of Canada, cutting an estimated $536K.

  • 22 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2024, down from 24 in Q2 2024.
  • Funds reported $7.55M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2024, down 7.1% quarter-over-quarter.
  • 4 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2024 and 6 closed out, a net change of -2 holders.
  • The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2024 was NewEdge Advisors, an estimated $611K added.
  • The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2024 was Royal Bank of Canada, an estimated $536K sold.

Based on aggregated 13F filings for Q3 2024.